Precision Medicine Initiatives at FDA
*Lisa LaVange, FDA 


In this collaborative presentation, I will describe various initiatives ongoing at FDA in the area of personalized or precision medicine. Examples based on our experience with targeted therapies, enrichment trial designs, and master protocols will be provided. The statistical reviewer’s involvement in these initiatives is important and will be discussed. Future directions for personalized medicine and their applicability in a regulatory setting will also be discussed.